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S U M M A R Y
Melioidosis is an endemic disease in Southeast Asia and northern Australia. It habitually affects immune-
depressed hosts and may have a wide range of clinical manifestations. The use of positron emission
tomography–computed tomography (PET-CT) has not been described previously for this disease. We
report the case of a European traveler without comorbidities who developed melioidosis with
pulmonary and bone marrow involvement 1 year after exposure. Antibiotic treatment was managed by
taking into account the evolution on PET-CT. We review the literature and suggest the use of PET-CT for
the initial evaluation of melioidosis, especially to look for a bone location, and to manage the length of
antibiotic therapy.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Melioidosis is an endemic disease in Southeast Asia and
northern Australia, caused by a Gram-negative bacillus, Burkhol-
deria pseudomallei. It may affect almost any organ in the body.
Reactivation from a latent focus of melioidosis is rare but possible
(5–10%) despite prolonged eradication phase treatment, especially
in the case of initial bacteremia.1
The use of positron emission tomography–computed tomogra-
phy (PET-CT) has not been described previously for this disease.
We report the case of an unusual presentation of the disease and
the ﬁrst published use of PET-CT in melioidosis. We review the
literature and suggest the use of this exam in the management of
melioidosis.
2. Case report
A previously healthy 55-year-old Caucasian man presented to
our hospital with a high fever of 40 8C, night sweats, weight loss of
6 kg over the previous 6 months, and right shoulder pain. His* Corresponding author. Tel.: +33 1 46 25 25 79; fax: +33 1 46 25 26 20.
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5 years earlier. He had travelled to Cambodia 1 year ago, where he
had led a healthy lifestyle and had had no cutaneous wounds or
contact with water.
The examination was normal. Laboratory test results showed an
elevated serum C-reactive protein (CRP) level at 30 mg/l, normal
white blood cell count, and a negative HIV serology. Blood cultures
were negative. An X-ray showed osteolytic lesions of the right arm
and shoulder, conﬁrmed by magnetic resonance imaging (MRI). An
18F-ﬂuorodeoxyglucose (18F-FDG) PET-CT revealed intense uptake
in the right humerus (maximum standard uptake value (SUVmax)
= 7.3) and in a pulmonary lesion (SUVmax = 1.8) identiﬁed as a
small lung cavitation on CT scan (Figure 1).
A surgical bone biopsy of the right humerus showed giant-cell
granuloma with necrosis. Acid-fast stains of bone and bronchial
biopsies were negative, but bone marrow culture allowed the
isolation of B. pseudomallei.
A 4-week treatment of intravenous ceftazidime (100 mg/kg/
day) and oral trimethoprim–sulfamethoxazole (TMP–SMX, 50 mg–
10 mg/kg/day) was started. Because of a drug-induced skin rash,
TMP–SMX was switched to doxycycline (6.5 mg/kg/day) during the
prolonged eradication phase, in association with amoxicillin–
clavulanate (3 g–375 mg/day). Susceptibility to these antibiotics
was previously assessed in vitro. The shoulder pain disappearedses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Top row, at diagnosis: left, osteolytic lesion of the right humerus with intense uptake of 18F-FDG; middle and right, lung CT scan showing cavitary lesion in the left
lower lobe; right, moderate 18F-FDG uptake of the cavitary lesion. Bottom row, after 6 months of treatment: left, disappearance of 18F-FDG uptake in the right humerus;
middle, consolidation of the cavitary lesion; right, disappearance of 18F-FDG uptake in the lung lesion.
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treatment showed persistent osteolytic lesions of the right
humerus with gadolinium uptake. However, PET-CT performed
after 6 months showed complete normalization of the humeral and
pulmonary SUVmax (Figure 1), allowing discontinuation of
antibiotics.
3. Discussion
B. pseudomallei, also known as Whitmore’s bacillus, is a Gram-
negative, aerobic, environmental bacterium found in soil and
water in Southeast Asia and northern Australia. Melioidosis is
usually acquired during the rainy season, by inhalation or by
inoculation through non-intact skin. Although unusual, vertical
transmission at birth, nosocomial transmission, zoonotic trans-
mission, and laboratory acquired infection have been recorded.
The main risk factors for melioidosis are diabetes, alcohol use,
chronic lung disease, chronic renal disease, and any situation
inducing immunosuppression.
Melioidosis covers a wide spectrum of severity, ranging from
chronic disease to fulminant sepsis, and may affect almost any
organ in the body.2 The acute form is the most frequent, commonly
associated with lung location. Melioidosis may also present as a
chronic illness, with the additional presence of internal chronic
abscesses. In one of the most important prospective cohorts
published to date, which included 540 patients with culture-
conﬁrmed melioidosis, the most common manifestations were
pneumonia (51%), genito-urinary infection (14%), skin infection
(13%), and sepsis without a clinical focus (13%).1 Bone or joint
locations concerned 4% of cases. Mortality varies greatly from 50%
in Cambodia and Thailand3 to 9% in Australia,1 and increases with
age (50 years), and the presence of at least one risk factor as
pulmonary location of melioidosis, septic shock (occurring in about
21% of all cases), or bacteremia.1–4B. pseudomallei is usually identiﬁed by conventional techniques,
including Gram stain and aerobic culture on agar media. For non-
sterile specimens, Ashdown’s selective medium is preferred, if
available. Bacteremia is identiﬁed in more than half of cases,1 and
melioidosis represents about 10% of blood stream infections and
10% of acute lower respiratory infections of bacteriological etiology
in Cambodia.3,4 Even though the performance of serological tests
has improved recently, their use is limited to areas with a low
prevalence, since most of the population is seropositive in endemic
areas.
B. pseudomallei shows natural resistance to a large number of
antimicrobial agents, including all narrow-spectrum cephalospor-
ins, most penicillins, macrolides, all aminoglycosides, and poly-
myxins. However, it is generally susceptible to chloramphenicol,
TMP–SMX, tetracyclines, third-generation cephalosporins, ureido-
penicillins, carbapenems, and amoxicillin–clavulanate. Although a
proportion of B. pseudomallei isolates are susceptible to ﬂuor-
oquinolones by in vitro testing, clinical evidence indicates that
ﬂuoroquinolones are not effective.
Antimicrobial therapy for melioidosis is divided into acute and
eradication phases. One of the current recommendations for the
acute phase, used in the largest Australian cohort, is a combination of
parenteral antimicrobial agents for at least 14 days with ceftazidime
(50 mg/kg, up to 2 g, 6-hourly) or meropenem (25 mg/kg, up to 1 g, 8-
hourly).5 In cases of deep-seated infections (e.g., central nervous
system infection or osteomyelitis), TMP–SMX may be added because
of its high tissue penetration. For the eradication phase, TMP–SMX
alone with folic acid supplements for at least 12 weeks may be
sufﬁcient, even if a four-drug regimen (chloramphenicol, doxycy-
cline, and TMP–SMX) is commonly used in Thailand. Doxycycline
should not be considered alone, and its addition to TMP–SMX for the
eradication phase remains debatable.5
Our observation is unusual regarding the occurrence of
melioidosis in a European traveler without comorbidities, about
1 year after exposure. This case shows that melioidosis must be
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returning from an endemic area like Southeast Asia or northern
Australia, especially when tuberculosis has been ruled out.
We also suggest that PET-CT may be useful for the initial
assessment of melioidosis locations, especially to look for
asymptomatic ones (e.g., the pulmonary cavitation in our case),
and to guide the duration of antibiotics in the eradication phase. In
the presented case, PET-CT showed complete healing more
accurately than MRI, which displayed chronic abnormalities
related to bone marrow remodeling after osteomyelitis.
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